Want to see SHTDY full AI Analyst Report?
Top Page
Sinopharm Group Co
(OTC:SHTDY)
Select Model
Select Model
Rating:61Neutral
Price Target:
$10.50
▲(4.17% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by middling financial performance—softening revenue, margin compression, and higher 2025 leverage offset by still-positive earnings and decent cash conversion. Valuation is the main positive (low P/E and solid dividend yield), while technicals are neutral with only modest near-term momentum and weaker long-term trend versus the 100/200-day averages.
Positive Factors
Nationwide healthcare distribution network
A nationwide distribution network serving institutional and retail healthcare customers gives Sinopharm broad commercial reach and supports recurring product flow across multiple channels. This scale can reinforce customer access and make the core distribution model durable over the next several quarters.
Negative Factors
Recent revenue contraction
Recent revenue contraction shows that the company’s earlier growth has not continued consistently. A declining top line can reduce operating leverage, limit investment capacity, and make it harder for Sinopharm to offset cost pressures through higher volume over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Nationwide healthcare distribution network
A nationwide distribution network serving institutional and retail healthcare customers gives Sinopharm broad commercial reach and supports recurring product flow across multiple channels. This scale can reinforce customer access and make the core distribution model durable over the next several quarters.
Read all positive factors
Sinopharm Group Co (SHTDY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.33B
Dividend Yield4.95%
Average Volume (3M)5.94K
Price to Earnings (P/E)6.0
Beta (1Y)0.09
Revenue Growth2.49%
EPS Growth7.42%
CountryUS
Employees94,910
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)11.15
Shares Outstanding268,362,150
10 Day Avg. Volume0
30 Day Avg. Volume5,938
Financial Highlights & Ratios
PEG Ratio-4.41
Price to Book (P/B)0.64
Price to Sales (P/S)0.10
P/FCF Ratio4.32
Enterprise Value/Market Cap3.70
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.60
Enterprise Value/Ebitda1.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinopharm Group Co Business Overview & Revenue Model
Company Description
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pha...
How the Company Makes Money
Sinopharm Group generally makes money through: (1) Pharmaceutical and healthcare product distribution: The core revenue stream is selling pharmaceuticals and other healthcare products (including medicines, medical devices, and consumables) to inst...
Sinopharm Group Co Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
52
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 563.46B | 559.50B | 584.51B | 596.57B | 552.15B | 521.05B |
| Gross Profit | 39.34B | 40.09B | 44.26B | 48.51B | 47.43B | 44.05B |
| EBITDA | 21.29B | 20.50B | 22.55B | 26.90B | 26.25B | 24.68B |
| Net Income | 6.99B | 6.96B | 7.05B | 9.05B | 8.53B | 7.76B |
Balance Sheet | ||||||
| Total Assets | 404.57B | 390.61B | 392.83B | 383.39B | 364.78B | 335.41B |
| Cash, Cash Equivalents and Short-Term Investments | 41.90B | 61.60B | 54.31B | 63.81B | 55.22B | 43.54B |
| Total Debt | 81.32B | 108.65B | 76.39B | 73.78B | 69.59B | 68.37B |
| Total Liabilities | 268.18B | 256.36B | 266.14B | 263.08B | 254.71B | 235.76B |
| Stockholders Equity | 85.22B | 84.01B | 78.88B | 74.58B | 68.07B | 61.89B |
Cash Flow | ||||||
| Free Cash Flow | 20.67B | 12.52B | 9.58B | 14.84B | 18.55B | 7.05B |
| Operating Cash Flow | 22.20B | 14.14B | 11.55B | 17.17B | 20.96B | 9.31B |
| Investing Cash Flow | -552.41M | -963.89M | -3.75B | -944.53M | -3.59B | -1.27B |
| Financing Cash Flow | -27.38B | -18.69B | -17.29B | -7.64B | -5.69B | -14.69B |
Sinopharm Group Co Technical Analysis
Positive
10.08
Price Trends
9.82
Positive
10.25
Negative
11.25
Negative
Market Momentum
0.11
Negative
57.84
Neutral
74.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHTDY, the sentiment is Positive. The current price of 10.08 is above the 20-day moving average (MA) of 9.79, above the 50-day MA of 9.82, and below the 200-day MA of 11.25, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 57.84 is Neutral, neither overbought nor oversold. The STOCH value of 74.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SHTDY.
Sinopharm Group Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $63.07B | 24.45 | 106.43% | 0.73% | 5.09% | 38.10% | |
71 Outperform | $114.36B | 26.14 | -194.39% | 0.35% | 8.84% | 48.98% | |
62 Neutral | $58.14B | 34.54 | -59.73% | 0.82% | 14.23% | 12.28% | |
61 Neutral | $6.33B | 6.01 | 8.33% | 4.95% | 2.49% | 7.42% | |
61 Neutral | $9.63B | 24.98 | 12.37% | ― | 6.49% | 10.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $26.18M | -1.66 | 23.64% | ― | -23.90% | -45.45% |
* Healthcare Sector Average
SHTDY
Sinopharm Group Co
10.32
-1.65
-13.82%
COR
Cencora
330.84
-4.42
-1.32%
CAH
Cardinal Health
250.48
61.50
32.54%
HSIC
Henry Schein
84.88
21.68
34.30%
MCK
McKesson
994.58
186.42
23.07%
YI
111
2.85
-1.52
-34.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.